NIIMBL technology action plans and technology roadmaps guide activities related to key biopharmaceutical manufacturing challenges and opportunities.
The NIIMBL Action Plan for Increasing Flexibility of Antibody Manufacturing for Rapid Response aims to accelerate industry adoption of next-generation manufacturing technologies for antibody production to enable rapid response to emerging health needs and speed product time to market.
NIIMBL technology roadmaps propose solutions to critical manufacturing challenges in three key topic areas: Antibody-Drug Conjugates (ADC) and Bispecific Antibodies, Gene Therapies, and Vaccines.
The Institute convened subject matter experts from industry, academic institutions, non-profits, and federal agencies to survey the current landscape and identify areas of opportunity for each of these product classes. The process also included participants focused on workforce development and regulatory considerations.
NIIMBL’s industry roadmap efforts will continue as we address additional topics.
Our industry roadmap efforts will continue as we address additional topics.
We offer a variety of membership options that give you the flexibility to choose your organization’s level of engagement based on technology interests and priorities.
